The cannabis industry was built on medical cannabis; now it’s time to return to it

Their recent publication in Nature's Scientific Reports highlights the use of Cannabis-Responsive (C-Res) biomarkers and machine learning to pioneer personalized therapies for ASD and various neurological conditions such as Azlheimer's disease, Multiple Sclerosis, and PTSD.

The first study of its kind will explore cannabis-responsive biomarkers in children with autism spectrum disorder (ASD).

Read More >

"Receiving IRB approval is an important milestone for Cannformatics as it shows our commitment to providing medical and scientific data that improves medical cannabis wellness outcomes," said Cannformatics CEO and cofounder Dr. Itzhak Kurek.

Read More >

Whether they know it, anyone who has ever consumed cannabis has sparked an interaction between cannabinoids and a network of...

Read More >

Whether they know it, anyone who has ever consumed cannabis has sparked an interaction between cannabinoids and a network of...

Read More >

The human body is remarkably good at protecting itself. The moment the body finds a xenobiotic, a foreign compound not made by...

Read More >

Though medical cannabis research is expanding daily, for patients and their health-care professionals, it's challenging to understand the...

Read More >

Researchers have made great strides in discovering how medical cannabis works in the body, but individual patients may still wonder...

Read More >

Two weeks ago, the National Cannabis Industry Association (NCIA) hosted the Cannabis Summit and Expo in San Jose, California.

Read More >